For example, monoclonal antibodies like bezlotoxumab for C. difficile neutralize toxins, conjugate vaccines like PCV20 restore serotype coverage, and checkpoint inhibitors like PD-1/PD-L1 blockade boost T-cell responses in tuberculosis models (12, 29). This evidence concerns the gene CD274 and tuberculosis.